irbesartan diabetic nephropathy trial Recently Published Documents

Insulin Dependent ◽

Kidney Disease Progression ◽

Post Hoc ◽

Faculty Opinions recommendation of Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725503819.793507757 ◽

2015 ◽

Author(s):

Luis Ruilope ◽

Enrique Morales

Keyword(s):

Diabetic Nephropathy ◽

Angiotensin Ii ◽

Kidney Disease ◽

Serum Bicarbonate ◽

Post Hoc Analysis ◽

Insulin Dependent ◽

Kidney Disease Progression ◽

Post Hoc ◽

Visit-to-Visit Variability in Blood Pressure and Kidney and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Nephropathy: A Post Hoc Analysis From the RENAAL Study and the Irbesartan Diabetic Nephropathy Trial

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2014.06.008 ◽

2014 ◽

Vol 64 (5) ◽

pp. 714-722 ◽

Cited By ~ 39

Author(s):

Ciaran J. McMullan ◽

Hiddo J. Lambers Heerspink ◽

Hans-Henrik Parving ◽

Jamie P. Dwyer ◽

John P. Forman ◽

...

Keyword(s):

Blood Pressure ◽

Type 2 Diabetes ◽

Diabetic Nephropathy ◽

Cardiovascular Outcomes ◽

Post Hoc Analysis ◽

Post Hoc ◽

Faculty Opinions recommendation of Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718509953.793498052 ◽

2014 ◽

Author(s):

Kazuomi Kario ◽

Michiaki Nagai

Keyword(s):

Blood Pressure ◽

Type 2 Diabetes ◽

Diabetic Nephropathy ◽

Cardiovascular Outcomes ◽

Post Hoc Analysis ◽

Post Hoc ◽

Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non–Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2013.09.016 ◽

2014 ◽

Vol 63 (2) ◽

pp. 244-250 ◽

Cited By ~ 41

Author(s):

Hiddo J. Lambers Heerspink ◽

Misghina Weldegiorgis ◽

Lesley A. Inker ◽

Ron Gansevoort ◽

Hans-Henrik Parving ◽

...

Keyword(s):

Diabetic Nephropathy ◽

Angiotensin Ii ◽

Kidney Failure ◽

Estimated Gfr ◽

Post Hoc Analysis ◽

Insulin Dependent ◽

Gfr Decline ◽

Post Hoc ◽

Faculty of 1000 evaluation for Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT).

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718171154.793487536 ◽

2013 ◽

Author(s):

Enyu Imai

Keyword(s):

Diabetic Nephropathy ◽

Angiotensin Ii ◽

Kidney Failure ◽

Estimated Gfr ◽

Post Hoc Analysis ◽

Insulin Dependent ◽

Gfr Decline ◽

Post Hoc ◽

Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfr696 ◽

2011 ◽

Vol 27 (6) ◽

pp. 2255-2263 ◽

Cited By ~ 26

Author(s):

Marc Evans ◽

Stephen C. Bain ◽

Simon Hogan ◽

Rudy W. Bilous

Keyword(s):

Diabetic Nephropathy ◽

Glomerular Filtration Rate ◽

Glomerular Filtration ◽

Filtration Rate ◽

Estimated Glomerular Filtration Rate ◽

Post Hoc Analysis ◽

Post Hoc ◽

Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical Implications and Limitations

Yearbook of Medicine ◽

10.1016/s0084-3873(08)70441-3 ◽

2006 ◽

Vol 2006 ◽

pp. 208-209

Author(s):

R. Garrick

Keyword(s):

Blood Pressure ◽

Diabetic Nephropathy ◽

Angiotensin Ii ◽

Blood Pressure Control ◽

Pressure Control ◽

Clinical Implications ◽

Receptor Blockade ◽

Angiotensin Ii Receptor ◽

Angiotensin Ii Receptor Blockade ◽

Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical Implications and Limitations

Journal of the American Society of Nephrology ◽

10.1681/asn.2004110919 ◽

2005 ◽

Vol 16 (10) ◽

pp. 3027-3037 ◽

Cited By ~ 241

Author(s):

Marc A. Pohl ◽

Samuel Blumenthal ◽

Daniel J. Cordonnier ◽

Fernando De Alvaro ◽

Giacomo DeFerrari ◽

...

Keyword(s):

Blood Pressure ◽

Diabetic Nephropathy ◽

Angiotensin Ii ◽

Blood Pressure Control ◽

Pressure Control ◽

Clinical Implications ◽

Receptor Blockade ◽

Angiotensin Ii Receptor ◽

Angiotensin Ii Receptor Blockade ◽

Impact of Achieved Blood Pressure on Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial

Journal of the American Society of Nephrology ◽

10.1681/asn.2004090763 ◽

2005 ◽

Vol 16 (7) ◽

pp. 2170-2179 ◽

Cited By ~ 216

Author(s):

Tomas Berl ◽

Lawrence G. Hunsicker ◽

Julia B. Lewis ◽

Marc A. Pfeffer ◽

Jerome G. Porush ◽

...

Keyword(s):

Blood Pressure ◽

Diabetic Nephropathy ◽

Cardiovascular Outcomes ◽